EntreMed (ENMD) Presents ENMD-2076 Data at ASCO
More News related to ENMD
- EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
- EntreMed Inc. (ENMD) Posts Break-Even Q3 EPS, 4c Better Y/Y
- EntreMed Reports Third Quarter 2009 Financial Results
- Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
- EntreMed (ENMD) Presents ENMD-2076 Data at ASCO
EntreMed, Inc. (Nasdaq: ENMD) announced the presentation of clinical data for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at ASCO.
ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and other kinases critical to angiogenesis, cellular growth and proliferation, was studied in patients with refractory solid tumors. Data from the 25 patients who participated demonstrated that ENMD-2076 administered orally in daily doses is associated with clinical benefit as determined by reductions in tumor volume, reductions in tumor markers, and improvement in cancer-related symptoms. These benefits were demonstrated in patients with a variety of tumor types including melanoma, renal cell, ovarian and colorectal cancer. ENMD-2076 was well-tolerated when administered daily.
More from Release
Related Categories
FDAStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
